TY - JOUR
T1 - Understanding kidney care needs and implementation strategies in low- and middle-income countries
T2 - conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
AU - Jha, Vivekanand
AU - Arici, Mustafa
AU - Collins, Allan J.
AU - Garcia-Garcia, Guillermo
AU - Hemmelgarn, Brenda R.
AU - Jafar, Tazeen H.
AU - Pecoits-Filho, Roberto
AU - Sola, Laura
AU - Swanepoel, Charles R.
AU - Tchokhonelidze, Irma
AU - Wang, Angela Yee Moon
AU - Kasiske, Bertram L.
AU - Wheeler, David C.
AU - Spasovski, Goce
AU - Agodoa, Lawrence
AU - Ahmad, Ghazali
AU - Anantharaman, Vathsala
AU - Arogundade, Fatiu
AU - Ashuntantang, Gloria
AU - Ballal, Sudarshan
AU - Bamgboye, Ebun
AU - Banchuin, Chatri
AU - Bogov, Boris
AU - Bunnag, Sakarn
AU - Chailimpamontri, Worawon
AU - Chawanasuntorapoj, Ratana
AU - Claure-Del Granado, Rolando
AU - Eiam-Ong, Somchai
AU - Gomez, Lynn
AU - Gómez, Rafael
AU - Goumenos, Dimitrios
AU - Phan, Hai An Ha
AU - Imonje, Valentine
AU - Ingsathit, Atiporn
AU - Jarraya, Faiçal
AU - Jiwakanon, Sirin
AU - Kantachuvesiri, Surasak
AU - Khanna, Umesh
AU - Kher, Vijay
AU - Kitositrangsikun, Kamol
AU - Liu, Zhi Hong
AU - Lorvinitnun, Pichet
AU - Nseka, Nazaire
AU - Obrador, Gregorio T.
AU - Okpechi, Ikechi
AU - Onsuwan, Duangta
AU - Ophascharoensuk, Vuddhidej
AU - Osafo, Charlotte
AU - Peiris, David
AU - Pichaiwong, Warangkana
AU - Praditpornsilpa, Kearkiat
AU - Rajapurkar, Mohan
AU - Rychlik, Ivan
AU - Saadi, Gamal
AU - Polo, Vicente Sanchez
AU - Sangthawan, Pornpen
AU - Suwan, Nirut
AU - Tesar, Vladimir
AU - Thirakhupt, Prapaipim
AU - Trakarnvanich, Thananda
AU - Tsukamoto, Yusuke
AU - Tungsanga, Kriang
AU - Vanichakarn, Supat
AU - Vazelov, Evgueniy
AU - Wanner, Christoph
AU - Were, Anthony
AU - Zakharova, Elena
N1 - Funding Information:
VJ declared having received research support from Baxter and GlaxoSmithKline. AJC declared having received consultancy fees from AstraZeneca, Bayer, Gilead, and Relypsa. GG-G declared having received consultancy fees from Pisa Farmaceutica and speaker honoraria from Abbvie. THJ declared having received research support from Wellcome Trust UK, Medical Research Council, Department for International Development, and Singapore Ministry of Health. RP-F declared having received consultancy fees from Akebia and Janssen; speaker honoraria from AstraZeneca, Janssen, and Novartis; and research support from Fresenius. CRS declared having received consultancy fees from Fresenius. AYMW declared having received speaker honoraria from Sanofi. DCW declared having received consultancy fees from Akebia, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Otsuka, UCB Celltech, and Vifor; speaker honoraria from Amgen, Fresenius, Janssen, Vifor, and ZS Pharma; and research support from British Heart Foundation, Healthcare Quality Improvement Partnership, Kidney Research UK, National Institute for Health Research, and Australian National Health & Medical Research Council. All the other authors declared no competing interests.
Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Fresenius Medical Care, Roche, Sandoz Biopharmaceuticals, and Sanofi.
Publisher Copyright:
© 2016 International Society of Nephrology
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Evidence-based cinical practice guidelines improve delivery of uniform care to patients with and at risk of developing kidney disease, thereby reducing disease burden and improving outcomes. These guidelines are not well-integrated into care delivery systems in most low- and middle-income countries (LMICs). The KDIGO Controversies Conference on Implementation Strategies in LMIC reviewed the current state of knowledge in order to define a road map to improve the implementation of guideline-based kidney care in LMICs. An international group of multidisciplinary experts in nephrology, epidemiology, health economics, implementation science, health systems, policy, and research identified key issues related to guideline implementation. The issues examined included the current kidney disease burden in the context of health systems in LMIC, arguments for developing policies to implement guideline-based care, innovations to improve kidney care, and the process of guideline adaptation to suit local needs. This executive summary serves as a resource to guide future work, including a pathway for adapting existing guidelines in different geographical regions.
AB - Evidence-based cinical practice guidelines improve delivery of uniform care to patients with and at risk of developing kidney disease, thereby reducing disease burden and improving outcomes. These guidelines are not well-integrated into care delivery systems in most low- and middle-income countries (LMICs). The KDIGO Controversies Conference on Implementation Strategies in LMIC reviewed the current state of knowledge in order to define a road map to improve the implementation of guideline-based kidney care in LMICs. An international group of multidisciplinary experts in nephrology, epidemiology, health economics, implementation science, health systems, policy, and research identified key issues related to guideline implementation. The issues examined included the current kidney disease burden in the context of health systems in LMIC, arguments for developing policies to implement guideline-based care, innovations to improve kidney care, and the process of guideline adaptation to suit local needs. This executive summary serves as a resource to guide future work, including a pathway for adapting existing guidelines in different geographical regions.
KW - acute kidney injury
KW - advocacy
KW - chronic kidney disease
KW - clinical practice guidelines
KW - implementation
KW - low and middle income countries
UR - http://www.scopus.com/inward/record.url?scp=84997327482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84997327482&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2016.09.009
DO - 10.1016/j.kint.2016.09.009
M3 - Article
C2 - 27884311
AN - SCOPUS:84997327482
VL - 90
SP - 1164
EP - 1174
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 6
ER -